AAAAAA

   
Results: 1-11 |
Results: 11
Progress in active-specific immunotherapy of brain malignancies
Authors: Tjoa, BA Salgaller, ML
Citation: Ba. Tjoa et Ml. Salgaller, Progress in active-specific immunotherapy of brain malignancies, EXPERT OP I, 9(9), 2000, pp. 2093-2101
Prostate cancer immunotherapy at the dawn of the new millennium
Authors: Salgaller, ML
Citation: Ml. Salgaller, Prostate cancer immunotherapy at the dawn of the new millennium, EXPERT OP I, 9(6), 2000, pp. 1217-1229
Immunologic approaches to antigen discovery for cancer vaccines
Authors: Jones, LA Salgaller, ML
Citation: La. Jones et Ml. Salgaller, Immunologic approaches to antigen discovery for cancer vaccines, EXPERT OP I, 9(3), 2000, pp. 481-489
Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
Authors: Lodge, PA Jones, LA Bader, RA Murphy, GP Salgaller, ML
Citation: Pa. Lodge et al., Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial, CANCER RES, 60(4), 2000, pp. 829-833
Peptides in prostate cancer
Authors: Salgaller, ML
Citation: Ml. Salgaller, Peptides in prostate cancer, MED INTEL U, 24, 2000, pp. 155-171
Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells
Authors: Lodge, PA Childs, RA Monahan, SJ McLean, JG Sehgal, A Boynton, AL Salgaller, ML Murphy, GP
Citation: Pa. Lodge et al., Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells, J IMMUNOTH, 22(4), 1999, pp. 346-355
Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1
Authors: Lake, DF Salgaller, ML van der Bruggen, P Bernstein, RM Marchalonis, JJ
Citation: Df. Lake et al., Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1, INT IMMUNOL, 11(5), 1999, pp. 745-751
Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
Authors: Murphy, GP Tjoa, BA Simmons, SJ Ragde, H Rogers, M Elgamal, A Kenny, GM Troychak, MJ Salgaller, ML Boynton, AL
Citation: Gp. Murphy et al., Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment, PROSTATE, 39(1), 1999, pp. 54-59
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
Authors: Murphy, GP Tjoa, BA Simmons, SJ Jarisch, J Bowes, VA Ragde, H Rogers, M Elgamal, A Kenny, GM Cobb, OE Ireton, RC Troychak, MJ Salgaller, ML Boynton, AL
Citation: Gp. Murphy et al., Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease, PROSTATE, 38(1), 1999, pp. 73-78
Report from the International Union Against Cancer (UICC) Tumor Biology Committee - UICC workshop on the use of dendritic cells in cancer clinical trials
Authors: Salgaller, ML Thurnher, M Bartsch, G Boynton, AL Murphy, GP
Citation: Ml. Salgaller et al., Report from the International Union Against Cancer (UICC) Tumor Biology Committee - UICC workshop on the use of dendritic cells in cancer clinical trials, CANCER, 86(12), 1999, pp. 2674-2683
Dendritic cell-based immunotherapy for prostate cancer
Authors: Tjoa, BA Lodge, PA Salgaller, ML Boynton, AL Murphy, GP
Citation: Ba. Tjoa et al., Dendritic cell-based immunotherapy for prostate cancer, CA-A CANC J, 49(2), 1999, pp. 117
Risultati: 1-11 |